PL3321279T3 - Modyfikator eksenatydu i jego zastosowanie - Google Patents

Modyfikator eksenatydu i jego zastosowanie

Info

Publication number
PL3321279T3
PL3321279T3 PL16848039T PL16848039T PL3321279T3 PL 3321279 T3 PL3321279 T3 PL 3321279T3 PL 16848039 T PL16848039 T PL 16848039T PL 16848039 T PL16848039 T PL 16848039T PL 3321279 T3 PL3321279 T3 PL 3321279T3
Authority
PL
Poland
Prior art keywords
exenatide modifier
exenatide
modifier
Prior art date
Application number
PL16848039T
Other languages
English (en)
Inventor
Jiandong Yuan
Yangqing HUANG
Yunsong SONG
Fang Yuan
Original Assignee
Brightgene Bio-Medical Technology Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brightgene Bio-Medical Technology Co., Ltd. filed Critical Brightgene Bio-Medical Technology Co., Ltd.
Publication of PL3321279T3 publication Critical patent/PL3321279T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/605Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/2278Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
PL16848039T 2015-09-25 2016-09-13 Modyfikator eksenatydu i jego zastosowanie PL3321279T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510619012.7A CN106554403B (zh) 2015-09-25 2015-09-25 艾塞那肽修饰物及其用途
PCT/CN2016/098844 WO2017050157A1 (zh) 2015-09-25 2016-09-13 艾塞那肽修饰物及其用途
EP16848039.0A EP3321279B1 (en) 2015-09-25 2016-09-13 Exenatide modifier and use thereof

Publications (1)

Publication Number Publication Date
PL3321279T3 true PL3321279T3 (pl) 2020-10-19

Family

ID=58385848

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16848039T PL3321279T3 (pl) 2015-09-25 2016-09-13 Modyfikator eksenatydu i jego zastosowanie

Country Status (19)

Country Link
US (1) US11179467B2 (pl)
EP (1) EP3321279B1 (pl)
JP (1) JP6647387B2 (pl)
KR (1) KR102005294B1 (pl)
CN (1) CN106554403B (pl)
AU (1) AU2016328015B9 (pl)
CA (1) CA2995613C (pl)
CY (1) CY1122760T1 (pl)
DK (1) DK3321279T3 (pl)
ES (1) ES2775185T3 (pl)
HR (1) HRP20200332T1 (pl)
HU (1) HUE048411T2 (pl)
LT (1) LT3321279T (pl)
PL (1) PL3321279T3 (pl)
PT (1) PT3321279T (pl)
RS (1) RS60053B1 (pl)
SI (1) SI3321279T1 (pl)
SM (1) SMT202000117T1 (pl)
WO (1) WO2017050157A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111333714A (zh) * 2020-03-05 2020-06-26 成都奥达生物科技有限公司 一种长效glp-1化合物
US12552742B2 (en) 2020-04-10 2026-02-17 Fresenius Kabi Oncology Ltd Process for the preparation of Semaglutide side chain
CN112939771A (zh) * 2021-01-28 2021-06-11 宁夏蓝博思化学技术有限公司 长链烷基二酸单叔丁酯的制备方法
US12215133B2 (en) 2021-03-25 2025-02-04 Brightgene Bio-Medical Technology Co., Ltd. GIP and GLP-1 dual receptor agonist, pharmaceutical composition, and use
CN115124602B (zh) * 2021-03-25 2024-01-26 博瑞生物医药(苏州)股份有限公司 Gip和glp-1的双受体激动剂、药物组合物及用途
JP2025531387A (ja) * 2022-09-23 2025-09-19 ブライトジーン プライベート リミティド Glp-1とgipの二重受容体アゴニスト医薬組成物及びその用途
CN119930756A (zh) * 2023-11-02 2025-05-06 博瑞生物医药(苏州)股份有限公司 一种gip和glp-1的双受体激动剂的制备方法
CN117736118B (zh) * 2023-12-15 2024-10-18 四川普康药业有限公司 Fmoc-AEEA的合成方法
CN117820136A (zh) * 2023-12-25 2024-04-05 康羽生命科学技术(苏州)有限公司 2-(2-(2-氨基乙氧基)乙氧基)乙酸的合成方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003522099A (ja) 1998-02-27 2003-07-22 ノボ ノルディスク アクティーゼルスカブ 遅延作用プロファイルを有するglp−1のglp−1誘導体及びエキセンジン
NZ512663A (en) 1999-01-14 2004-05-28 Amylin Pharmaceuticals Inc Novel exendin agonist formulations and methods of administration thereof
JP2007537981A (ja) 2003-09-19 2007-12-27 ノボ ノルディスク アクティーゼルスカブ 新規の血漿タンパク質親和性タグ
TWI372629B (en) * 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
JP5755398B2 (ja) * 2005-03-18 2015-07-29 ノヴォ ノルディスク アー/エス 伸長されたglp−1化合物
CN101125207B (zh) 2006-11-14 2012-09-05 上海华谊生物技术有限公司 带有聚乙二醇基团的艾塞丁或其类似物及其制剂和用途
CN101215324B (zh) 2007-12-26 2010-11-24 吉林大学 艾塞那肽短肽模拟肽及其在制备糖尿病治疗药物中的应用
MX2010008024A (es) 2008-02-01 2010-12-21 Ascendis Pharma As Profarmaco que comprende un enlazador que se puede separar por si mismo.
US20110171164A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of glp-2-like peptides
CN101870728A (zh) 2009-04-23 2010-10-27 派格生物医药(苏州)有限公司 新型Exendin变体及其缀合物
CN102397558B (zh) 2010-09-09 2013-08-14 中国人民解放军军事医学科学院毒物药物研究所 Exendin-4类似物的定位聚乙二醇化修饰物及其用途
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate
US20140256626A1 (en) 2011-10-18 2014-09-11 Prolynx Llc Peg conjugates of exenatide
CN102532303A (zh) 2011-12-22 2012-07-04 江苏弘和药物研发有限公司 聚乙二醇缀合的艾塞那肽的合成及应用
CN102827270A (zh) 2012-09-13 2012-12-19 无锡和邦生物科技有限公司 一种聚乙二醇化艾塞那肽衍生物及其用途
CN103405753B (zh) * 2013-08-13 2016-05-11 上海仁会生物制药股份有限公司 稳定的促胰岛素分泌肽水针药物组合物
KR101768446B1 (ko) * 2014-03-21 2017-08-17 애니젠 주식회사 신규한 엑세나타이드 유사체 및 그의 용도

Also Published As

Publication number Publication date
US20200101162A1 (en) 2020-04-02
CA2995613A1 (en) 2017-03-30
AU2016328015A1 (en) 2018-03-01
HUE048411T2 (hu) 2020-07-28
DK3321279T3 (da) 2020-03-09
SI3321279T1 (sl) 2020-07-31
KR20180031740A (ko) 2018-03-28
AU2016328015B2 (en) 2018-10-25
PT3321279T (pt) 2020-03-05
CN106554403B (zh) 2021-08-31
WO2017050157A1 (zh) 2017-03-30
US11179467B2 (en) 2021-11-23
SMT202000117T1 (it) 2020-03-13
CA2995613C (en) 2021-07-20
JP2018531217A (ja) 2018-10-25
KR102005294B1 (ko) 2019-07-30
JP6647387B2 (ja) 2020-02-14
AU2016328015A9 (en) 2018-11-01
RS60053B1 (sr) 2020-04-30
ES2775185T3 (es) 2020-07-24
AU2016328015B9 (en) 2018-12-06
CY1122760T1 (el) 2021-03-12
EP3321279A1 (en) 2018-05-16
EP3321279A4 (en) 2018-05-16
CN106554403A (zh) 2017-04-05
HRP20200332T1 (hr) 2020-06-12
EP3321279B1 (en) 2020-02-12
LT3321279T (lt) 2020-04-10

Similar Documents

Publication Publication Date Title
IL255577B (en) Binding materials - tigit and their uses
IL253433A0 (en) Binders - tnfrsf and their uses
PL3250692T3 (pl) Promotor i jego zastosowania
IL247014A0 (en) 6-heteroaryloxy and 6-aryloxy-quinoline-2-carboxamides and their use
IL264813B (en) 2-oxo-imidazopyridines and their use
IL254977B (en) Biological conjugates and their uses
SMT202000117T1 (it) Modificatore di exenatide e suo uso
ZA202108600B (en) Anti-tnfalpha-antibodies and functional fragments thereof
SG11202000029PA (en) Anti-tnfalpha-antibodies and functional fragments thereof
ZA201801052B (en) Combinations and uses thereof
IL256020B (en) Igfbp3 and uses thereof
IL265531A (en) N 3 -cyclically substituted thienouraciles and use thereof
IL261261A (en) Antibodies against tnf-alpha and functional fragments thereof
IL261098A (en) Antibodies against tnf-alpha and functional fragments thereof
IL254241A0 (en) Etv2 and its uses
IL261793A (en) Anti-tnfalpha antibodies and their functional parts
GB2545167B (en) Cloches and use thereof
GB201500278D0 (en) Novel combination and use
PT2923578T (pt) Método para a produção de um produto alimentar